Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-0616 in Participants With Varying Degrees of Renal Impairment
NCT05934292Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity, AUC From Time 0 to Last Measurable Concentration and 5 more. Started Jul 2023; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05934292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934292.